There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myelogenous leukemia (CML) arises from the constitutive activity of the BCR-ABL1
oncoprotein. Tyrosine kinase inhibitors (TKIs) that target the ATP-binding site have …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically,
resistance can arise prior to or as a result of cancer therapy. In this review, we discuss …

Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all
BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including …

Asciminib is a potent, orally bioavailable, investigational drug that specifically and potently
inhibits the tyrosine kinase activity of native ABL1, together with that of the chimeric BCR …